Materiały źródłowe

• #1 RSV Linked to High Burden of Hospitalizations Prior to Vaccine Availability

  https://www.infectiousdiseaseadvisor.com/news/rsv-linked-to-high-burden-of-hospitalizations-prior-to-vaccine-availability/

  Prior to the introduction of respiratory syncytial virus (RSV) vaccines, RSV was linked to a substantial burden of hospitalizations, admissions to the intensive care unit, and in-hospital deaths among adults, especially those aged 75 and older. […] Respiratory syncytial virus (RSV) infection was associated with a substantial burden of hospitalizations, intensive care unit (ICU) admissions, and in-hospital deaths in adults prior to the introduction of the RSV vaccines in 2023, according to study findings published in JAMA Network Open. […] Investigators conducted a cross-sectional study across 7 surveillance seasons (2016-2017 through 2022-2023) to determine the burden of RSV-associated hospitalizations among US adults before the introduction of RSV vaccines. […] Given the large numbers of potentially vaccine-preventable hospitalizations and deaths associated with RSV, increasing vaccine coverage among adults at highest risk could reduce associated hospitalizations and severe clinical outcomes.

• #2 :: IC :: Infection & Chemotherapy

  https://icjournal.org/DOIx.php?id=10.3947/ic.2024.0011

  Respiratory syncytial virus (RSV) constitutes a significant cause of respiratory illness and mortality among older adults, a demographic that is expanding with considerable impact on healthcare systems worldwide. […] The actual burden of RSV in this population may still be underestimated, owing to factors such as low awareness and suboptimal diagnostic sensitivity in adults, the lack of robust RSV surveillance systems, and the infrequent use of diagnostic testing. […] The recent approval of two vaccines highlights the critical need for the precise estimation of the RSV disease burden to optimize the effectiveness and cost-efficiency of immunization programs. […] These epidemiologic changes, coupled with the approval of vaccines for older adults, underscore the need for a detailed understanding of the epidemiology and disease burden of RSV infection.

• #3 Surveillance of RSV | RSV | CDC

  https://www.cdc.gov/rsv/php/surveillance/index.html

  CDC maintains multiple systems to monitor respiratory diseases, including RSV, across the United States. […] CDC has several systems that focus on monitoring and describing seasonal trends, clinical risk factors, rates of illness and hospitalization, and demographics of patients seeking care for illness associated with respiratory syncytial virus (RSV). […] The National Respiratory and Enteric Virus Surveillance System (NREVSS) is a laboratory-based system that monitors seasons and circulation patterns of RSV and other viruses. […] The RSV Hospitalization Surveillance Network (RSV-NET) is a population-based surveillance system for RSV-associated hospitalizations in the U.S. among children and adults. […] The New Vaccine Surveillance Network (NVSN) is a multisite, active, population-based pediatric surveillance network for acute respiratory hospitalizations and outpatient visits associated with RSV and other respiratory pathogens.

• #4 Surveillance of RSV | RSV | CDC

  https://www.cdc.gov/rsv/php/surveillance/index.html

  CDC maintains multiple systems to monitor respiratory diseases, including RSV, across the United States. […] CDC has several systems that focus on monitoring and describing seasonal trends, clinical risk factors, rates of illness and hospitalization, and demographics of patients seeking care for illness associated with respiratory syncytial virus (RSV). […] The National Respiratory and Enteric Virus Surveillance System (NREVSS) is a laboratory-based system that monitors seasons and circulation patterns of RSV and other viruses. […] The RSV Hospitalization Surveillance Network (RSV-NET) is a population-based surveillance system for RSV-associated hospitalizations in the U.S. among children and adults. […] The New Vaccine Surveillance Network (NVSN) is a multisite, active, population-based pediatric surveillance network for acute respiratory hospitalizations and outpatient visits associated with RSV and other respiratory pathogens.

• #5 Surveillance of RSV | RSV | CDC

  https://www.cdc.gov/rsv/php/surveillance/index.html

  CDC collects RSV laboratory test results performed in the United States using the National Respiratory and Enteric Virus Surveillance System (NREVSS). CDC analyzes data on RSV activity at the national, regional, and state levels. […] Data from NREVSS provide information to public health officials and healthcare providers about the presence of RSV in their communities.

• #6 Surveillance of RSV | RSV | CDC

  https://www.cdc.gov/rsv/php/surveillance/index.html

  CDC maintains multiple systems to monitor respiratory diseases, including RSV, across the United States. […] CDC has several systems that focus on monitoring and describing seasonal trends, clinical risk factors, rates of illness and hospitalization, and demographics of patients seeking care for illness associated with respiratory syncytial virus (RSV). […] The National Respiratory and Enteric Virus Surveillance System (NREVSS) is a laboratory-based system that monitors seasons and circulation patterns of RSV and other viruses. […] The RSV Hospitalization Surveillance Network (RSV-NET) is a population-based surveillance system for RSV-associated hospitalizations in the U.S. among children and adults. […] The New Vaccine Surveillance Network (NVSN) is a multisite, active, population-based pediatric surveillance network for acute respiratory hospitalizations and outpatient visits associated with RSV and other respiratory pathogens.

• #7 RSV-NET | RSV | CDC

  https://www.cdc.gov/rsv/php/surveillance/rsv-net.html

  CDC uses RSV-NET hospitalization data, combined with mathematical and statistical models, to inform in-season RSV disease burden estimates, updated weekly. […] RSV-NET currently comprises 161 counties and county equivalents in 13 states participating in the Respiratory Virus Surveillance Network. […] RSV-NET surveillance began tracking RSV-associated hospitalizations in adults in the 20162017 season and in children in the 20182019 season. […] Hospitalization rates are calculated as the number of residents in a surveillance area who are hospitalized with laboratory-confirmed RSV divided by the total population estimate for that area.

• #8 Surveillance of RSV | RSV | CDC

  https://www.cdc.gov/rsv/php/surveillance/index.html

  CDC maintains multiple systems to monitor respiratory diseases, including RSV, across the United States. […] CDC has several systems that focus on monitoring and describing seasonal trends, clinical risk factors, rates of illness and hospitalization, and demographics of patients seeking care for illness associated with respiratory syncytial virus (RSV). […] The National Respiratory and Enteric Virus Surveillance System (NREVSS) is a laboratory-based system that monitors seasons and circulation patterns of RSV and other viruses. […] The RSV Hospitalization Surveillance Network (RSV-NET) is a population-based surveillance system for RSV-associated hospitalizations in the U.S. among children and adults. […] The New Vaccine Surveillance Network (NVSN) is a multisite, active, population-based pediatric surveillance network for acute respiratory hospitalizations and outpatient visits associated with RSV and other respiratory pathogens.

• #9 Meeting reports

  https://www.who.int/teams/global-influenza-programme/global-respiratory-syncytial-virus-surveillance

  The WHO has implemented the RSV surveillance strategy based on GISRS since 2015. […] A standardized and robust global Respiratory Syncytial Virus (RSV) surveillance system is important to better understand the seasonality of RSV infections. […] Respiratory syncytial virus (RSV) is the leading viral cause of acute lower respiratory tract infections in infants and young children in whom this virus.

• #10 RSV vaccines | AusVaxSafety

  https://www.ausvaxsafety.org.au/vaccine-safety-data/rsv-vaccines

  AusVaxSafety is conducting active vaccine safety surveillance of recently introduced respiratory syncytial virus (RSV) vaccines in Australia to ensure their ongoing safety. […] Safety data are gathered via the AusVaxSafety surveillance program and are based on vaccine safety surveys sent in the days following RSV vaccination. Data on this page are updated monthly. […] Vaccine safety data for additional population groups and other RSV vaccines will be added once enough data are collected to enable meaningful analysis. […] AusVaxSafety publishes Australian-first safety data for Arexvy RSV vaccine.

• #11 Respiratory syncytial virus (RSV) FAQs | NCIRS

  https://ncirs.org.au/ncirs-fact-sheets-faqs-and-other-resources/respiratory-syncytial-virus-rsv-frequently-asked

  A single dose of RSV vaccine (Arexvy or Abrysvo) is recommended for people aged 75 years and over, First Nations people aged 60 years and over, and adults aged 60 years and over with conditions that increase their risk of severe RSV disease. […] In Australia, RSV hospitalisations are more common in winter however, they can occur year-round. Seasonal peaks are less noticeable in tropical regions such as the Northern Territory and North Queensland. […] The reported rate of RSV hospitalisations in older adults has been increasing with the growing awareness of RSV disease and more frequent laboratory testing in this age cohort. […] The Abrysvo vaccine is now (as of 3 February 2025) being funded under the NIP for pregnant women. […] In 2025, state- and territory-funded programs will also provide free monoclonal antibody product (Beyfortus [nirsevimab]) for infants who are not protected through maternal vaccination and at-risk infants and children.

• #12 Respiratory syncytial virus (RSV) | The Australian Immunisation Handbook

  https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/respiratory-syncytial-virus-rsv

  RSV is a leading cause of lower respiratory tract infection, particularly in infants and older people. Almost all children experience RSV infection within the first 2 years of life. People at increased risk of RSV infection include preterm infants, people with certain medical conditions, and Aboriginal and Torres Strait Islander people. […] RSV activity varies and is primarily climate-driven. Seasonal outbreaks in most temperate regions in Australia occur during autumn and winter, usually between April and September. The season peaks during June and July, often preceding the influenza season. In tropical regions, RSV seasonality can be less pronounced and may coincide with rainy seasons. RSV subtypes A and B co-circulate, but one may be dominant and this may change from year to year. […] Children aged <5 years predominantly account for RSV-associated hospitalisations, with the highest rate in infants during the first few months of life (approximately 3100 per 100,000 population aged 0–2 months). RSV-associated hospitalisation rates generally decline starting in early childhood, and begin to steadily increase in adults from the 50–65-year age cohort. Among young children, RSV causes a disproportionately high disease burden, particularly in those born preterm. In children aged <5 years, one study showed that those born at <28 weeks gestation have a hospitalisation rate approximately 8 times higher than the overall rate, and those born at 28–31 weeks gestation have a hospitalisation rate approximately 5 times higher. Aboriginal and Torres Strait Islander children also have approximately 2 times higher RSV hospitalisation rates compared with non-Indigenous children.

• #13 What’s New

  https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/RSV.aspx

  RSV (Respiratory Syncytial Virus) is a common respiratory virus that causes colds but can be severe for infants and older adults. It can spread when someone with the virus sneezes or coughs, through close contact with someone who is sick, or by touching infected surfaces and then touching your face without first washing your hands. People with RSV infection typically have fever, cough, runny nose, wheezing and in very young infants increased irritability and difficulty breathing. Learn more about RSV symptoms and how to care for people with RSV. […] In most years, RSV is most common between October through March. RSV can spread at the same time as COVID-19 and influenza (flu), so its important to protect yourself and others with immunizations from all three viruses. […] RSV immunizations are recommended for older adults, pregnant people, and infants.

• #14 Respiratory syncytial virus (RSV) | The Australian Immunisation Handbook

  https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/respiratory-syncytial-virus-rsv

  Available data show a 20-fold increase in RSV-associated hospitalisation rates in adults aged ≥65 years between 2006 and 2015 compared with other adults. This is mostly attributable to increased testing and recognition of RSV in the older adult population. The burden of disease in Australian adults is likely underestimated due to infrequent testing in previous years, which is now increasing. To adjust for this possible underestimation, a study that modelled Australian RSV-attributable hospitalisations in adults aged ≥75 years showed the hospitalisation rate to be 256 per 100,000. […] During the COVID-19 pandemic, RSV activity substantially declined and seasonality was disrupted. However, RSV activity since the 2022–23 season in the Northern Hemisphere and 2023 season in Australia suggests a return towards a pre-pandemic seasonal pattern.

• #15 Deviations in RSV epidemiological patterns and population structures in the United States following the COVID-19 pandemic | Nature Communications

  https://www.nature.com/articles/s41467-024-47757-9

  Respiratory Syncytial Virus (RSV) is a leading cause of acute respiratory tract infection, with the greatest impact on infants, immunocompromised individuals, and older adults. RSV prevalence decreased substantially in the United States (US) following the implementation of COVID-19-related non-pharmaceutical interventions but later rebounded with abnormal seasonality. The biological and epidemiological factors underlying this altered behavior remain poorly defined. […] In 2023 the Food and Drug Administration (FDA) approved two first-in-class RSV vaccines for older adults and maternal immunization. The first adjuvanted vaccine (Arexy) reduced the risk of RSV-lower respiratory tract infection (LRTI) in older adults by 94.1%. The later unadjuvanted, bivalent vaccine (Abrysvo) reduced LRTI in older adults by 85.7% and in infants from vaccinated pregnant individuals by 81.5% within 90 days after birth.

• #16 Newer preventive options helping reduce RSV-associated hospitalization rates among infants – VUMC News

  https://news.vumc.org/2025/05/08/newer-preventive-options-helping-reduce-rsv-associated-hospitalization-rates-among-infants/

  Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. […] Recent findings of the impact of new RSV prevention products aimed at protecting babies were published in the Morbidity and Mortality Weekly Report, an epidemiological digest prepared by the Centers for Disease Control and Prevention. […] The introduction of a maternal RSV vaccination and the infant monoclonal antibody, nirsevimab, is associated with meaningful reductions in infant hospitalizations, said Natasha Halasa, MD, MPH, Craig-Weaver Professor of Pediatrics at Monroe Carell Jr. Childrens Hospital at Vanderbilt. […] The goal of the study was to compare RSV-associated hospitalization rates in the 2024-2025 season with pre-COVID seasons (2018-2020) to see if these products made a difference they did, said Halasa, one of the study investigators.

• #17 Respiratory syncytial virus (RSV) | The Australian Immunisation Handbook

  https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/respiratory-syncytial-virus-rsv

  RSV is a leading cause of lower respiratory tract infection, particularly in infants and older people. Almost all children experience RSV infection within the first 2 years of life. People at increased risk of RSV infection include preterm infants, people with certain medical conditions, and Aboriginal and Torres Strait Islander people. […] RSV activity varies and is primarily climate-driven. Seasonal outbreaks in most temperate regions in Australia occur during autumn and winter, usually between April and September. The season peaks during June and July, often preceding the influenza season. In tropical regions, RSV seasonality can be less pronounced and may coincide with rainy seasons. RSV subtypes A and B co-circulate, but one may be dominant and this may change from year to year. […] Children aged <5 years predominantly account for RSV-associated hospitalisations, with the highest rate in infants during the first few months of life (approximately 3100 per 100,000 population aged 0–2 months). RSV-associated hospitalisation rates generally decline starting in early childhood, and begin to steadily increase in adults from the 50–65-year age cohort. Among young children, RSV causes a disproportionately high disease burden, particularly in those born preterm. In children aged <5 years, one study showed that those born at <28 weeks gestation have a hospitalisation rate approximately 8 times higher than the overall rate, and those born at 28–31 weeks gestation have a hospitalisation rate approximately 5 times higher. Aboriginal and Torres Strait Islander children also have approximately 2 times higher RSV hospitalisation rates compared with non-Indigenous children.

• #18 Respiratory syncytial virus (RSV) FAQs | NCIRS

  https://ncirs.org.au/ncirs-fact-sheets-faqs-and-other-resources/respiratory-syncytial-virus-rsv-frequently-asked

  Respiratory syncytial virus (RSV) is a common virus that can cause a range of respiratory illnesses from mild upper respiratory colds to severe lower respiratory conditions such as bronchiolitis (in infants) and pneumonia. […] The RSV-associated hospitalisation rate is highest in infants under 6 months of age and generally declines sharply with age from early childhood. Hospitalisation rates then increase again in late adulthood. […] The National RSV Mother Infant Protection Program (RSV-MIPP), which commenced on 3 February 2025, is providing pregnant women with free access to the Abrysvo vaccine under the National Immunisation Program (NIP). […] RSV immunisation products are not currently funded for other recommended population groups. […] A single dose of Abrysvo vaccine is recommended and NIP-funded for pregnant women of all ages from 28 weeks gestation to protect the infant via passive immunisation.

• #19 Respiratory syncytial virus (RSV) | The Australian Immunisation Handbook

  https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/respiratory-syncytial-virus-rsv

  RSV is a leading cause of lower respiratory tract infection, particularly in infants and older people. Almost all children experience RSV infection within the first 2 years of life. People at increased risk of RSV infection include preterm infants, people with certain medical conditions, and Aboriginal and Torres Strait Islander people. […] RSV activity varies and is primarily climate-driven. Seasonal outbreaks in most temperate regions in Australia occur during autumn and winter, usually between April and September. The season peaks during June and July, often preceding the influenza season. In tropical regions, RSV seasonality can be less pronounced and may coincide with rainy seasons. RSV subtypes A and B co-circulate, but one may be dominant and this may change from year to year. […] Children aged <5 years predominantly account for RSV-associated hospitalisations, with the highest rate in infants during the first few months of life (approximately 3100 per 100,000 population aged 0–2 months). RSV-associated hospitalisation rates generally decline starting in early childhood, and begin to steadily increase in adults from the 50–65-year age cohort. Among young children, RSV causes a disproportionately high disease burden, particularly in those born preterm. In children aged <5 years, one study showed that those born at <28 weeks gestation have a hospitalisation rate approximately 8 times higher than the overall rate, and those born at 28–31 weeks gestation have a hospitalisation rate approximately 5 times higher. Aboriginal and Torres Strait Islander children also have approximately 2 times higher RSV hospitalisation rates compared with non-Indigenous children.

• #20 Respiratory syncytial virus (RSV) | The Australian Immunisation Handbook

  https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/respiratory-syncytial-virus-rsv

  RSV is a leading cause of lower respiratory tract infection, particularly in infants and older people. Almost all children experience RSV infection within the first 2 years of life. People at increased risk of RSV infection include preterm infants, people with certain medical conditions, and Aboriginal and Torres Strait Islander people. […] RSV activity varies and is primarily climate-driven. Seasonal outbreaks in most temperate regions in Australia occur during autumn and winter, usually between April and September. The season peaks during June and July, often preceding the influenza season. In tropical regions, RSV seasonality can be less pronounced and may coincide with rainy seasons. RSV subtypes A and B co-circulate, but one may be dominant and this may change from year to year. […] Children aged <5 years predominantly account for RSV-associated hospitalisations, with the highest rate in infants during the first few months of life (approximately 3100 per 100,000 population aged 0–2 months). RSV-associated hospitalisation rates generally decline starting in early childhood, and begin to steadily increase in adults from the 50–65-year age cohort. Among young children, RSV causes a disproportionately high disease burden, particularly in those born preterm. In children aged <5 years, one study showed that those born at <28 weeks gestation have a hospitalisation rate approximately 8 times higher than the overall rate, and those born at 28–31 weeks gestation have a hospitalisation rate approximately 5 times higher. Aboriginal and Torres Strait Islander children also have approximately 2 times higher RSV hospitalisation rates compared with non-Indigenous children.

• #21 Respiratory syncytial virus (RSV) vaccines: Canadian Immunization Guide – Canada.ca

  https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html

  Immunization of older adults with RSV vaccine can reduce medically attended RSV respiratory tract infections and hospitalizations due to RSV. […] RSV exhibits a seasonal infection cycle that is somewhat variable by region. In temperate climates in the Northern Hemisphere, annual RSV outbreaks begin in the fall and continue to early spring. […] In Canada, approximately 2% of all infants are hospitalized with RSV in their first year of life. […] RSV is not a notifiable disease in Canada, consequently the burden and risk of RSV in older adults is likely underestimated. […] RSV vaccines can be administered at the same time as, or at any time before or after, other vaccines.

• #22 Respiratory syncytial virus (RSV) FAQs | NCIRS

  https://ncirs.org.au/ncirs-fact-sheets-faqs-and-other-resources/respiratory-syncytial-virus-rsv-frequently-asked

  Respiratory syncytial virus (RSV) is a common virus that can cause a range of respiratory illnesses from mild upper respiratory colds to severe lower respiratory conditions such as bronchiolitis (in infants) and pneumonia. […] The RSV-associated hospitalisation rate is highest in infants under 6 months of age and generally declines sharply with age from early childhood. Hospitalisation rates then increase again in late adulthood. […] The National RSV Mother Infant Protection Program (RSV-MIPP), which commenced on 3 February 2025, is providing pregnant women with free access to the Abrysvo vaccine under the National Immunisation Program (NIP). […] RSV immunisation products are not currently funded for other recommended population groups. […] A single dose of Abrysvo vaccine is recommended and NIP-funded for pregnant women of all ages from 28 weeks gestation to protect the infant via passive immunisation.

• #23 RSV Linked to High Burden of Hospitalizations Prior to Vaccine Availability

  https://www.infectiousdiseaseadvisor.com/news/rsv-linked-to-high-burden-of-hospitalizations-prior-to-vaccine-availability/

  Prior to the introduction of respiratory syncytial virus (RSV) vaccines, RSV was linked to a substantial burden of hospitalizations, admissions to the intensive care unit, and in-hospital deaths among adults, especially those aged 75 and older. […] Respiratory syncytial virus (RSV) infection was associated with a substantial burden of hospitalizations, intensive care unit (ICU) admissions, and in-hospital deaths in adults prior to the introduction of the RSV vaccines in 2023, according to study findings published in JAMA Network Open. […] Investigators conducted a cross-sectional study across 7 surveillance seasons (2016-2017 through 2022-2023) to determine the burden of RSV-associated hospitalizations among US adults before the introduction of RSV vaccines. […] Given the large numbers of potentially vaccine-preventable hospitalizations and deaths associated with RSV, increasing vaccine coverage among adults at highest risk could reduce associated hospitalizations and severe clinical outcomes.

• #24 RSV Vaccines Would Greatly Reduce Illness if Implemented Like Flu Shots < Yale School of Public Health

  https://ysph.yale.edu/news-article/new-rsv-vaccines-would-dramatically-reduce-illness-and-death-in-us-if-implemented-at-influenza-vaccination-levels/

  Respiratory syncytial virus (RSV) vaccines recently approved for people 60 and older would dramatically reduce the diseases significant burden of illness and death in the United States if they were widely adopted like annual influenza vaccines, a new study has found. […] RSV causes substantial morbidity and mortality among the elderly in the U.S. and globally, but this is the first time that RSV vaccines have been available, said senior author Alison Galvani, PhD, the Burnett and Stender Families Professor of Epidemiology (Microbial Diseases) at the Yale School of Public Health. […] Two RSV vaccines, Arexy and Abrysvo, were approved by the U.S. Food and Drug Administration earlier this year. RSV disease causes an estimated 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths annually in adults 65 and older, according to the Centers for Disease Control and Prevention (CDC).

• #25 Large, real world data analysis finds RSV vaccine 80% effective

  https://www.regenstrief.org/article/multi-state-study-finds-rsv-vaccine-highly-effective/

  Studies like this one are critical to understanding the effects of prevention techniques like vaccination. […] Preventing up to 80 percent of hospitalizations could result in major savings for consumers and the health system. […] In years prior to the availability of an RSV vaccine, an estimated 60,000 to 160,000 RSV-associated hospitalizations and 6,000 to 10,000 RSV-associated deaths occurred annually among U.S. adults aged 65 years and older, according to the CDC.

• #26 RSV vaccine effective in preventing hospitalizations in older Americans | CIDRAP

  https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/rsv-vaccine-effective-preventing-hospitalizations-older-americans

  Today, The Lancet published the first real-world data analysis of respiratory syncytial virus (RSV) vaccine efficacy among older US adults in a large multistate study. The study shows the vaccine was 80% effective in protecting against hospitalizations and deaths during the 2023-2024 RSV season. […] The study was based on data collected via the electronic health records of patients seen at 230 hospitals and 245 emergency departments across the United States from October 2023 through April 2024. The hospitals are part of the Centers for Disease Control and Preventions (CDC’s) VISION network. […] Each year, the CDC estimates that 60,000 to 160,000 RSV-associated hospitalizations and 6,000 to 10,000 RSV-associated deaths will occur among adults aged 65 years and older. Before the introduction of the RSV vaccine last year, RSV hospitalizations for this group cost between $1.2 and $5 billion annually. […] Currently, the CDC recommends that all adults over 75 be vaccinated against RSV and adults over 60 if they are at risk for severe disease, including those who are obese or have heart disease, diabetes, or immune compromise.

• #27 RSV Linked to High Burden of Hospitalizations Prior to Vaccine Availability

  https://www.infectiousdiseaseadvisor.com/news/rsv-linked-to-high-burden-of-hospitalizations-prior-to-vaccine-availability/

  Adults aged 75 and older accounted for 45.6% (range, 43.1%-48.8%) of all hospitalizations, 38.6% (range, 36.7%-41.0%) of all ICU admissions, and 58.7% (range, 51.9%-67.1%) of all in-hospital deaths across all seasons. […] Given the large numbers of potentially vaccine-preventable hospitalizations and deaths associated with RSV, increasing vaccine coverage among adults at highest risk could reduce associated hospitalizations and severe clinical outcomes, the investigators concluded.

• #28 Respiratory syncytial virus (RSV) | The Australian Immunisation Handbook

  https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/respiratory-syncytial-virus-rsv

  Available data show a 20-fold increase in RSV-associated hospitalisation rates in adults aged ≥65 years between 2006 and 2015 compared with other adults. This is mostly attributable to increased testing and recognition of RSV in the older adult population. The burden of disease in Australian adults is likely underestimated due to infrequent testing in previous years, which is now increasing. To adjust for this possible underestimation, a study that modelled Australian RSV-attributable hospitalisations in adults aged ≥75 years showed the hospitalisation rate to be 256 per 100,000. […] During the COVID-19 pandemic, RSV activity substantially declined and seasonality was disrupted. However, RSV activity since the 2022–23 season in the Northern Hemisphere and 2023 season in Australia suggests a return towards a pre-pandemic seasonal pattern.

• #29 Respiratory Syncytial Virus | Florida Department of Health

  https://www.floridahealth.gov/diseases-and-conditions/respiratory-illness/respiratory-syncytial-virus/

  Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Young children and older adults, especially those with certain underlying health conditions, are at higher risk for severe illness from RSV. […] Individual cases of RSV are not reportable in Florida. All outbreaks of RSV are reportable. The Florida Department of Health will continue to make updates on the trends presented in this report as needed. […] Surveillance is conducted to support clinical decision-making for prophylaxis of premature infants. The determination of unique seasonal and geographic trends in RSV activity in Florida has important implications for prescribing patterns for initiating prophylaxis to children at high risk for complications from RSV infection. The American Academy of Pediatrics currently recommends pre-approval for prophylactic treatment be made based on state surveillance data. […] In 2023, two vaccines (Arexvy and Abrysvo) and a monoclonal antibody (nirsevimab) were approved for the prevention of RSV related illness. In 2024, a third vaccine (mResvia) was approved.

• #30 RSV (Respiratory Syncytial Virus) | Vermont Department of Health

  https://www.healthvermont.gov/disease-control/immunizations/rsv-respiratory-syncytial-virus

  RSV (Respiratory syncytial virus) is a common respiratory virus that generally spreads during fall and winter. Nearly all children will get RSV for the first time before the age of two. Its possible to get RSV more than once and people can get infected at any age. […] Vaccines are available to protect older adults from severe RSV. Vaccines for pregnant people or an RSV antibody is available to protect babies from severe RSV. […] All adults ages 75 and older should get an RSV vaccine. […] Adults ages 60-74 who are at increased risk of severe RSV should get an RSV vaccine. […] There are three RSV vaccines approved for use in adults 60 and older: GSK’s AREXVY, Moderna’s mRESVIA, and Pfizer’s ABRYSVO. […] RSV is the leading cause of hospitalization in infants in the U.S. […] All babies are recommended to be protected from severe RSV by one of two immunization options.

• #31 Newer preventive options helping reduce RSV-associated hospitalization rates among infants – VUMC News

  https://news.vumc.org/2025/05/08/newer-preventive-options-helping-reduce-rsv-associated-hospitalization-rates-among-infants/

  Investigators compared pediatric RSV-associated hospitalization rates from two U.S. active surveillance systems, the RSV-Associated Hospitalization Surveillance Network (RSV-NET) and the New Vaccine Surveillance Network (NVSN). […] RSV-NET conducts active population-based surveillance for laboratory-confirmed RSV-associated hospitalizations identified through clinical testing among catchment-area residents of all ages in more than 300 hospitals in 161 counties across 13 states. […] The first vaccines and monoclonal antibodies for RSV were approved by the Food and Drug Administration in May 2023 and became widely available during the 2024-2025 respiratory virus season. […] The CDC recommends early immunization with nirsevimab for all infants less than 8 months old to protect them from severe RSV. […] The report urges medical professionals and parents to continue to discuss RSV and the recommendations to help in prevention efforts. […] The findings from this study indicates that we are on the right path in reducing the risk of RSV hospitalizations in infants.

• #32 Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025 | MMWR

  https://www.cdc.gov/mmwr/volumes/74/wr/mm7416a1.htm?s_cid=mm7416a1_w

  Maternal respiratory syncytial virus (RSV) vaccine and nirsevimab, a long-acting monoclonal antibody, help prevent infant RSV-associated hospitalizations; these products became widely available in the United States during the 202425 RSV season. […] In this ecologic analysis comparing RSV-associated hospitalization rates among infants aged 07 months during 202425 with those during preCOVID-19 pandemic RSV seasons in two surveillance networks, rates during 202425 were lower by an estimated 28% and 43%. […] In the first RSV season with widespread availability of maternal vaccine and nirsevimab, RSV-associated hospitalization rates among infants were lower than in prepandemic seasons. Effective health care planning is needed to protect infants as early in the RSV season as possible through maternal vaccination during pregnancy or infant receipt of nirsevimab.

• #33 Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025 | MMWR

  https://www.cdc.gov/mmwr/volumes/74/wr/mm7416a1.htm?s_cid=mm7416a1_w

  To evaluate the association between availability of these products and infant and child RSV-associated hospitalization rates, the rates among children aged 5 years were compared for the 202425 and 201820 RSV seasons using data from the RSV-Associated Hospitalization Surveillance Network (RSV-NET) and New Vaccine Surveillance Network (NVSN). […] The findings suggest the importance of protecting infants born during the RSV season through either maternal vaccination during pregnancy or nirsevimab administration in the first week of life, ideally during the birth hospitalization. […] National immunization survey data indicate the estimated proportion of U.S. infants aged 07 months protected by either maternal vaccination or nirsevimab increased during the 202425 RSV season, from 30% in October 2024 to 66% in February 2025, coinciding with the 202425 RSV-associated hospitalization rate reductions in both surveillance networks, with the largest monthly reductions occurring during peak hospitalization periods. […] These results support the recommendations of the Advisory Committee on Immunization Practices to optimize population-level impact by administering RSV prevention products as early as possible in the season (i.e., before peak RSV transmission) on the basis of local epidemiology.

• #34 RSV vaccine effective in preventing hospitalizations in older Americans | CIDRAP

  https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/rsv-vaccine-effective-preventing-hospitalizations-older-americans

  Today, The Lancet published the first real-world data analysis of respiratory syncytial virus (RSV) vaccine efficacy among older US adults in a large multistate study. The study shows the vaccine was 80% effective in protecting against hospitalizations and deaths during the 2023-2024 RSV season. […] The study was based on data collected via the electronic health records of patients seen at 230 hospitals and 245 emergency departments across the United States from October 2023 through April 2024. The hospitals are part of the Centers for Disease Control and Preventions (CDC’s) VISION network. […] Each year, the CDC estimates that 60,000 to 160,000 RSV-associated hospitalizations and 6,000 to 10,000 RSV-associated deaths will occur among adults aged 65 years and older. Before the introduction of the RSV vaccine last year, RSV hospitalizations for this group cost between $1.2 and $5 billion annually. […] Currently, the CDC recommends that all adults over 75 be vaccinated against RSV and adults over 60 if they are at risk for severe disease, including those who are obese or have heart disease, diabetes, or immune compromise.

• #35 RSV vaccine 75% effective against hospitalization in older adults, CDC study estimates | CIDRAP

  https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/rsv-vaccine-75-effective-against-hospitalization-older-adults-cdc

  The respiratory syncytial virus (RSV) vaccine for older adults was 75% effective against hospitalization in its first season of use, adding to the findings of prelicensure trials, according to a test-negative, case-control analysis published today in JAMA. […] Researchers from the US Centers for Disease Control and Prevention (CDC) and Vanderbilt University conducted interviews and examined the electronic medical records of 2,978 adults aged 60 and older hospitalized with an acute respiratory illness at 24 centers in 19 states participating in a surveillance network from October 2023 to March 2024. […] An estimated 60,000 to 160,000 RSV hospital admissions occur each year among US adults aged 65 years and older. […] Evaluation of RSV VE in future seasons is important to confirm these findings and further examine VE among subgroups and by time since vaccination.

• #36 RSV (Respiratory Syncytial Virus) | Vermont Department of Health

  https://www.healthvermont.gov/disease-control/immunizations/rsv-respiratory-syncytial-virus

  The maternal RSV vaccine (Pfizers Abrysvo) is recommended if you are between 32 and 36 weeks pregnant during September through January in most of the U.S. […] An RSV antibody (nirsevimab) is recommended for all babies younger than 8 months of age born to mothers who did not receive a maternal RSV vaccine (Pfizers Abrysvo) during pregnancy. […] Early real-world data show that nirsevimab was 80-90% effective in preventing babies from being hospitalized with RSV. It provides immediate protection against RSV and lasts at least 5 months.

• #37 RSV Vaccines Would Greatly Reduce Illness if Implemented Like Flu Shots < Yale School of Public Health

  https://ysph.yale.edu/news-article/new-rsv-vaccines-would-dramatically-reduce-illness-and-death-in-us-if-implemented-at-influenza-vaccination-levels/

  The researchers analyzed how these outcomes would be reduced if 66% of adults 60 and older received an RSV vaccine. That is the typical influenza vaccination coverage for adults 65 years or older in the U.S. […] They found that 66% vaccination coverage in the first year reduced outpatient care by as much as 53.6%, hospitalizations by up to 60.5%, and RSV-related deaths by as much as 60.4%. […] Increasing vaccination coverage to 100% reduced outpatient care by up to 81.2%, hospitalizations by as much as 91.7%, and deaths by up to 91.3%. […] With the annual costs savings achieved from vaccination, a program where 66% of adults 60 and older are vaccinated for RSV would costs the U.S. health care system $6.4 to $7.1 billion for one season, and at 100% $9.7 to $10.7 billion at 100% vaccination, the researchers found.

• #38

  https://link.springer.com/article/10.1007/s40121-024-00939-w

  Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract disease in older adults, resulting in substantial morbidity and mortality. […] This study estimates the public health impact of vaccination with the adjuvanted RSVPreF3 vaccine among adults aged 60 years in the United States (US). […] In the base-case analysis, approximately 56.7 million adults aged 60 years received the vaccine, resulting in 2,954,465 fewer symptomatic RSV-ARI cases over 3 years compared with no vaccination, including 321,019 fewer X-ray confirmed pneumonia cases and 16,660 fewer RSV-related deaths. […] These findings highlight the potential of the adjuvanted RSVPreF3 vaccine to substantially reduce RSV disease burden among US older adults aged 60 years. […] The objective of this study was to estimate the public health impact of RSV vaccination with the adjuvanted RSVPreF3 vaccine compared with no vaccination in US adults aged 60 years. […] The model assumed vaccination in October to align with typical timing of influenza vaccinations. […] Assuming the same vaccination coverage as for influenza vaccines, the public health benefit of the adjuvanted RSVPreF3 vaccine in older adults is expected to be substantial.

• #39 Early Real-World Safety Data for RSV Vaccines

  https://www.uspharmacist.com/article/early-realworld-safety-data-for-rsv-vaccines

  In a recent publication in the CDCs Morbidity and Mortality Weekly Report, researchers published the first early real-world clinical safety data for the FDA-approved vaccines. […] Data from clinical trials indicate that GBS was identified as a potential safety concern. […] V-safe is a voluntary, active U.S. surveillance system that submits Web surveys to enrolled participants on Days 0 to 7 after vaccination, based on the reported vaccination date. […] VAERS is a voluntary surveillance system that accepts adverse event reports from the public, providers, and manufacturers. […] From May 3, 2023, to April 14, 2024, VAERS received and processed 3,200 reports of adverse events among individuals aged 60 years who reported receiving an RSV vaccine. […] The authors also reported that overall, 2,919 (91.2%) of events reported to the VAERS were classified as nonserious, with commonly reported adverse effects as pain in an extremity (13.2%), headache (12.9%), pain (12.8%), injection-site pain (12.7%), and fatigue (12.2%); however, VAERS recorded 28 reports of GBS that met the established case definition.

• #40 Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11973799/

  Our disproportionality analysis indicated signals for various AEs, particularly preterm birth, indicating that reports of preterm birth in conjunction with RSVpreF vaccination were observed more frequently than statistically expected. […] The AEs reported to VAERS among pregnant individuals vaccinated with RSVpreF largely aligned with the safety profile observed in prelicensure studies; however, this analysis also highlights the previously observed safety signal for preterm birth. […] Active surveillance studies focusing on maternal and perinatal outcomes are needed to further evaluate this signal and guide future clinical recommendations. […] The study uses the Vaccine Adverse Event Reporting System (VAERS) database, a U.S. national pharmacovigilance system, that provides a near real-time surveillance capacity for identifying rare adverse events not previously detected during prelicensure trials.

• #41 Early Real-World Safety Data for RSV Vaccines

  https://www.uspharmacist.com/article/early-realworld-safety-data-for-rsv-vaccines

  In a recent publication in the CDCs Morbidity and Mortality Weekly Report, researchers published the first early real-world clinical safety data for the FDA-approved vaccines. […] Data from clinical trials indicate that GBS was identified as a potential safety concern. […] V-safe is a voluntary, active U.S. surveillance system that submits Web surveys to enrolled participants on Days 0 to 7 after vaccination, based on the reported vaccination date. […] VAERS is a voluntary surveillance system that accepts adverse event reports from the public, providers, and manufacturers. […] From May 3, 2023, to April 14, 2024, VAERS received and processed 3,200 reports of adverse events among individuals aged 60 years who reported receiving an RSV vaccine. […] The authors also reported that overall, 2,919 (91.2%) of events reported to the VAERS were classified as nonserious, with commonly reported adverse effects as pain in an extremity (13.2%), headache (12.9%), pain (12.8%), injection-site pain (12.7%), and fatigue (12.2%); however, VAERS recorded 28 reports of GBS that met the established case definition.

• #42 AusVaxSafety publishes Australian-first safety data for Arexvy RSV vaccine | AusVaxSafety

  https://ausvaxsafety.org.au/ausvaxsafety-publishes-australian-first-safety-data-arexvy-rsv-vaccine

  Australian-first active respiratory syncytial virus (RSV) vaccine safety data, published by AusVaxSafety in the Lancet Regional Health Western Pacific, report low adverse event rates after Arexvy RSV vaccination. […] Safety surveillance data from more than 2,000 Arexvy vaccine recipients between 29 February 2024 when the vaccine became available in Australia through the private market for adults aged 60 years and older and 27 September 2024 showed that over 63% experienced no side effects in the first three days after vaccination. […] Dr Lucy Deng, AusVaxSafety Clinical Lead, said, This is the first post-marketing active surveillance data published in Australia for the Arexvy RSV vaccine and is testament to Australia’s commitment to ongoing vaccine safety through robust monitoring. […] Reassuringly, the rates of adverse events reported to AusVaxSafety following Arexvy RSV vaccination are consistent with expectations from clinical trial data and other international surveillance activities, Dr Deng continued.

• #43 Early Real-World Safety Data for RSV Vaccines

  https://www.uspharmacist.com/article/early-realworld-safety-data-for-rsv-vaccines

  In a recent publication in the CDCs Morbidity and Mortality Weekly Report, researchers published the first early real-world clinical safety data for the FDA-approved vaccines. […] Data from clinical trials indicate that GBS was identified as a potential safety concern. […] V-safe is a voluntary, active U.S. surveillance system that submits Web surveys to enrolled participants on Days 0 to 7 after vaccination, based on the reported vaccination date. […] VAERS is a voluntary surveillance system that accepts adverse event reports from the public, providers, and manufacturers. […] From May 3, 2023, to April 14, 2024, VAERS received and processed 3,200 reports of adverse events among individuals aged 60 years who reported receiving an RSV vaccine. […] The authors also reported that overall, 2,919 (91.2%) of events reported to the VAERS were classified as nonserious, with commonly reported adverse effects as pain in an extremity (13.2%), headache (12.9%), pain (12.8%), injection-site pain (12.7%), and fatigue (12.2%); however, VAERS recorded 28 reports of GBS that met the established case definition.

• #44 Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11973799/

  To describe the post-marketing safety profile of respiratory syncytial virus prefusion F (RSVpreF) vaccine among pregnant individuals. […] This study analysed adverse event (AE) reports submitted to the U.S. Food and Drug Administrations Vaccine Adverse Event Reporting System (VAERS) database following RSVpreF immunisation from 1 September 2023 to 23 February 2024. […] VAERS, as a national spontaneous vaccine safety surveillance system, provides insights into the safety profile of the RSVpreF vaccine in a real-world setting. […] Surveillance data included all AE reports submitted to VAERS in pregnant individuals following vaccination. […] Descriptive statistics were used to assess all AE reports with RSVpreF, including frequency, gestational age at vaccination, time to AE onset, reported outcomes and proportion of serious reports.

• #45 Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System – PubMed

  https://pubmed.ncbi.nlm.nih.gov/40187782/

  Objectives: To describe the post-marketing safety profile of respiratory syncytial virus prefusion F (RSVpreF) vaccine among pregnant individuals. […] This study analysed adverse event (AE) reports submitted to the U.S. Food and Drug Administration’s Vaccine Adverse Event Reporting System (VAERS) database following RSVpreF immunisation from 1 September 2023 to 23 February 2024. […] VAERS, as a national spontaneous vaccine safety surveillance system, provides insights into the safety profile of the RSVpreF vaccine in a real-world setting. […] Surveillance data included all AE reports submitted to VAERS in pregnant individuals following vaccination. […] Our disproportionality analysis indicated signals for various AEs, particularly preterm birth, indicating that reports of preterm birth in conjunction with RSVpreF vaccination were observed more frequently than statistically expected.

• #46 Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11973799/

  Our disproportionality analysis indicated signals for various AEs, particularly preterm birth, indicating that reports of preterm birth in conjunction with RSVpreF vaccination were observed more frequently than statistically expected. […] The AEs reported to VAERS among pregnant individuals vaccinated with RSVpreF largely aligned with the safety profile observed in prelicensure studies; however, this analysis also highlights the previously observed safety signal for preterm birth. […] Active surveillance studies focusing on maternal and perinatal outcomes are needed to further evaluate this signal and guide future clinical recommendations. […] The study uses the Vaccine Adverse Event Reporting System (VAERS) database, a U.S. national pharmacovigilance system, that provides a near real-time surveillance capacity for identifying rare adverse events not previously detected during prelicensure trials.

• #47 Early Real-World Safety Data for RSV Vaccines

  https://www.uspharmacist.com/article/early-realworld-safety-data-for-rsv-vaccines

  In a recent publication in the CDCs Morbidity and Mortality Weekly Report, researchers published the first early real-world clinical safety data for the FDA-approved vaccines. […] Data from clinical trials indicate that GBS was identified as a potential safety concern. […] V-safe is a voluntary, active U.S. surveillance system that submits Web surveys to enrolled participants on Days 0 to 7 after vaccination, based on the reported vaccination date. […] VAERS is a voluntary surveillance system that accepts adverse event reports from the public, providers, and manufacturers. […] From May 3, 2023, to April 14, 2024, VAERS received and processed 3,200 reports of adverse events among individuals aged 60 years who reported receiving an RSV vaccine. […] The authors also reported that overall, 2,919 (91.2%) of events reported to the VAERS were classified as nonserious, with commonly reported adverse effects as pain in an extremity (13.2%), headache (12.9%), pain (12.8%), injection-site pain (12.7%), and fatigue (12.2%); however, VAERS recorded 28 reports of GBS that met the established case definition.

• #48 Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 | MMWR

  https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm

  ACIP recognized that a risk-based recommendation for adults aged 6074 years might result in lower RSV vaccination coverage among persons at increased risk compared with an age-based recommendation for this group. […] However, ACIP judged that postlicensure safety surveillance suggests a potential increased risk for GBS after protein subunit RSV vaccination (GSK Arexvy and Pfizer Abrysvo), and although no GBS signal was observed after Moderna mResvia vaccination in RCTs, postlicensure safety surveillance has yet to occur. […] Based on currently available evidence, ACIP concluded that the benefits of RSV vaccination did not clearly outweigh the potential harms in adults aged 6074 years without risk factors for severe RSV disease.

• #49 Vaccines for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/vaccines/older-adults.html

  CDC recommends everyone ages 75 and older get an RSV vaccine. […] CDC recommends adults ages 60-74 who are at increased risk of severe RSV disease get an RSV vaccine. […] The RSV vaccine is not currently an annual vaccine. […] The RSV vaccine is given as a single dose. […] CDC recommends an RSV vaccine for all adults ages 75 years and older and for adults ages 60-74 years who are at increased risk of severe RSV. […] One dose of RSV vaccine provides protection against RSV disease in adults ages 60 years and older for at least two years. […] Additional data are needed for all three vaccines to determine how long the protection lasts. […] Based on the available data, ACIP and CDC continue to conclude that the benefits of RSV vaccination, in terms of preventable hospitalizations and deaths, outweigh the potential risk for GBS, among adults ages 75 years and older and among adults ages 60-74 years at increased risk of severe RSV disease. […] CDC and FDA will continue to monitor RSV vaccine safety and will share data as they become available.

• #50 Vaccines for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/vaccines/older-adults.html

  CDC recommends everyone ages 75 and older get an RSV vaccine. […] CDC recommends adults ages 60-74 who are at increased risk of severe RSV disease get an RSV vaccine. […] The RSV vaccine is not currently an annual vaccine. […] The RSV vaccine is given as a single dose. […] CDC recommends an RSV vaccine for all adults ages 75 years and older and for adults ages 60-74 years who are at increased risk of severe RSV. […] One dose of RSV vaccine provides protection against RSV disease in adults ages 60 years and older for at least two years. […] Additional data are needed for all three vaccines to determine how long the protection lasts. […] Based on the available data, ACIP and CDC continue to conclude that the benefits of RSV vaccination, in terms of preventable hospitalizations and deaths, outweigh the potential risk for GBS, among adults ages 75 years and older and among adults ages 60-74 years at increased risk of severe RSV disease. […] CDC and FDA will continue to monitor RSV vaccine safety and will share data as they become available.

• #51 Early Real-World Safety Data for RSV Vaccines

  https://www.uspharmacist.com/article/early-realworld-safety-data-for-rsv-vaccines

  The findings in this report are generally consistent with those from safety data collected in prelicensure clinical trials, including the observance of GBS cases. […] CDC and FDA are conducting active safety evaluations to assess risks for GBS and other adverse events of special interest after RSV vaccination.

• #52 Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 | MMWR

  https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm

  On June 21, 2023, the Advisory Committee on Immunization Practices (ACIP) recommended that adults aged 60 years may receive a single dose of respiratory syncytial virus (RSV) vaccine, using shared clinical decision-making. […] On June 26, 2024, ACIP voted to update these recommendations as follows: all adults aged 75 years and adults aged 6074 years who are at increased risk for severe RSV disease should receive a single dose of RSV vaccine. […] These updated recommendations are intended to maximize RSV vaccination coverage among persons most likely to benefit. Continued postlicensure monitoring will guide future recommendations. […] The 20232024 RSV season was the first during which RSV vaccination was recommended for U.S. adults aged 60 years, using shared clinical decision-making.

• #53 Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 | MMWR

  https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm

  To update adult RSV vaccination recommendations, ACIP considered data from previous meetings; new data from randomized, observer-blind, placebo-controlled clinical trials (RCTs) of mResvia; and postlicensure data on Arexvy and Abrysvo. […] ACIP recommended a single dose of any FDA-approved RSV vaccine for all adults aged 75 years and for adults aged 6074 years who are at increased risk for severe RSV disease. […] These recommendations replace the June 2023 shared clinical decision-making recommendation for RSV vaccination for adults aged 60 years and apply to all RSV vaccines licensed for adults aged 60 years (i.e., Arexvy [GSK], Abrysvo [Pfizer], or mResvia [Moderna]). […] The challenges of shared clinical decision-making, along with the updated evidence on balance of benefits and risks, led ACIP in June 2024 to make an age-based recommendation for adults aged 75 years and a risk-based recommendation for those aged 6074 years.

• #54 RSV Vaccines | RSV | CDC

  https://www.cdc.gov/rsv/vaccines/index.html

  RSV vaccines are recommended for all adults ages 75 and older and adults ages 60 74 who are at increased risk for severe RSV. […] There are two immunizations recommended to protect infants from severe RSV: a maternal RSV vaccine (Pfizer’s Abrysvo) given during pregnancy or an RSV antibody given to infants after birth. […] Immunizations to protect against severe RSV – Vaccine for adults ages 60 and over, babies during infancy, including vaccine given to mother during pregnancy. […] Information on vaccines to protect adults ages 60 and older against RSV. […] Surveillance.

• #55 Respiratory Syncytial Virus (RSV) Vaccines | CDC Recommendations | AAFP

  https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/disease-pop-immunization/rsv-vaccine.html

  Respiratory syncytial virus (RSV) is a common virus that affects the lungs, making breathing difficult. […] The CDC estimates that RSV causes approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths among older adults every year. […] The AAFP endorses the following RSV vaccination recommendations from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention: All adults 75 and older should receive a single dose of an RSV vaccine. Adults 60 to 74 who are at increased risk for severe RSV illness should receive a single dose of an RSV vaccine. […] The RSV vaccine is not currently an annual vaccine, so people who have previously received it do not need to get another dose. […] Vaccine administration errors are known to occur and are routinely monitored through the Vaccine Adverse Event Reporting System (VAERS). […] CDC, FDA, and other federal agencies continue to monitor the safety of RSV vaccines and reports of vaccine administration errors and will share information with the public as it becomes available.

• #56 ACIP Updates RSV Vaccination Recommendations in Older Adults – Pulmonology Advisor Older Adults RSV Vaccinations: ACIP Updates Recommendations

  https://www.pulmonologyadvisor.com/news/older-adults-rsv-vaccinations-updated-acip-guidance/

  The ACIP determined that RSV vaccination benefits do not clearly outweigh potential harms in adults aged 60 to 74 years not at risk for severe RSV. […] The Advisory Committee on Immunization Practices (ACIP) has recommended that all adults aged 75 years and older and those aged 60 to 74 years who have an increased risk for severe respiratory syncytial virus (RSV) disease should receive a single dose of RSV vaccine, as reported in the Morbidity and Mortality Weekly Report. […] ACIP judged that postlicensure safety surveillance suggests a potential increased risk for GBS after protein subunit RSV vaccination (GSK Arexvy and Pfizer Abrysvo). […] Postlicensure safety surveillance indicated a potential higher risk for GBS after protein subunit RSV vaccination (Arexvy and Abrysvo). […] ACIP judged that postlicensure safety surveillance suggests a potential increased risk for GBS after protein subunit RSV vaccination (GSK Arexvy and Pfizer Abrysvo), the report stated. Based on currently available evidence, ACIP concluded that the benefits of RSV vaccination did not clearly outweigh the potential harms in adults aged 60 to 74 years without risk factors for severe RSV disease. However, ACIP also stressed that research regarding RSV risk factors is ongoing, report authors noted.

• #57 Respiratory Syncytial Virus (RSV) Vaccines | CDC Recommendations | AAFP

  https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/disease-pop-immunization/rsv-vaccine.html

  Respiratory syncytial virus (RSV) is a common virus that affects the lungs, making breathing difficult. […] The CDC estimates that RSV causes approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths among older adults every year. […] The AAFP endorses the following RSV vaccination recommendations from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention: All adults 75 and older should receive a single dose of an RSV vaccine. Adults 60 to 74 who are at increased risk for severe RSV illness should receive a single dose of an RSV vaccine. […] The RSV vaccine is not currently an annual vaccine, so people who have previously received it do not need to get another dose. […] Vaccine administration errors are known to occur and are routinely monitored through the Vaccine Adverse Event Reporting System (VAERS). […] CDC, FDA, and other federal agencies continue to monitor the safety of RSV vaccines and reports of vaccine administration errors and will share information with the public as it becomes available.

• #58 What’s New

  https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/RSV.aspx

  RSV vaccines can help protect adults aged 75 and older and adults aged 60-74 who are at increased risk of severe RSV. […] Two immunization products are recommended by CDC to help children fight RSV infections and protect children from getting very sick from RSV: an RSV vaccine given during pregnancy or an RSV immunization given to a child after birth. […] RSV vaccine is recommended for pregnant people at 32 through 36 weeks of pregnancy during the months of September through January to prevent RSV infections in their infants. […] An RSV immunization called nirsevimab (Beyfortus) can help protect infants and toddlers from severe RSV illness. […] RSV immunizations for children should be covered by most private insurance plans. […] Resources for Public Health (Disease and Outbreak Investigation): Acute Respiratory Outbreak Report Form (PDF)

• #59 Vaccine Recommendations

  https://www.sandiegocounty.gov/content/sdc/hhsa/programs/phs/community_epidemiology/dc/respiratoryviruses/vaccinerecommendations.html

  1 dose of maternal RSV vaccine during weeks 32 through 36 of pregnant, administered September through January. […] RSV vaccine is not recommended for pregnant people who received it during a prior pregnancy. […] 1 dose of the RSV vaccine for everyone ages 75 and older and adults ages 60-74 at increased risk from getting very sick from RSV. […] RSV vaccine is not currently an annual vaccine, meaning older adults do not need to get a dose every RSV season.

• #60 What’s New

  https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/RSV.aspx

  RSV vaccines can help protect adults aged 75 and older and adults aged 60-74 who are at increased risk of severe RSV. […] Two immunization products are recommended by CDC to help children fight RSV infections and protect children from getting very sick from RSV: an RSV vaccine given during pregnancy or an RSV immunization given to a child after birth. […] RSV vaccine is recommended for pregnant people at 32 through 36 weeks of pregnancy during the months of September through January to prevent RSV infections in their infants. […] An RSV immunization called nirsevimab (Beyfortus) can help protect infants and toddlers from severe RSV illness. […] RSV immunizations for children should be covered by most private insurance plans. […] Resources for Public Health (Disease and Outbreak Investigation): Acute Respiratory Outbreak Report Form (PDF)

• #61 Vaccine Recommendations

  https://www.sandiegocounty.gov/content/sdc/hhsa/programs/phs/community_epidemiology/dc/respiratoryviruses/vaccinerecommendations.html

  Vaccines are available to protect older adults from getting very sick from RSV. Vaccines for pregnant people, or monoclonal antibody products, are available to protect infants and young children from getting very sick from RSV. […] The Centers for Disease Control and Prevention (CDC) recommends either maternal RSV vaccination or infant immunization with monoclonal antibodies. Most infants will not need both. […] 1 dose of nirsevimab for all infants younger than 8 months of age who were born shortly before, or are entering, their first RSV season (typically fall through spring). […] 1 dose of nirsevimab for infants and children 8-19 months old who are at increased risk for severe RSV disease and entering their second RSV season. […] A different monoclonal antibody, palivizumab, is limited to children under 24 months of age with certain conditions that place them at high risk for severe RSV disease. It must be given once a month during RSV season.

• #62

  https://www.sandiegocounty.gov/content/sdc/hhsa/programs/phs/community_epidemiology/dc/rsv.html

  RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. […] Vaccines are available to protect older adults from getting very sick from RSV. Vaccines for pregnant people, or monoclonal antibody products, are available to protect infants and young children from getting very sick from RSV. […] The Centers for Disease Control and Prevention (CDC) recommends either maternal RSV vaccination or infant immunization with monoclonal antibodies. Most infants will not need both. […] 1 dose of nirsevimab for all infants younger than 8 months of age who were born shortly before, or are entering, their first RSV season (typically fall through spring). […] 1 dose of nirsevimab for infants and children 8-19 months old who are at increased risk for severe RSV disease and entering their second RSV season.

• #63 Vaccines for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/vaccines/older-adults.html

  CDC recommends everyone ages 75 and older get an RSV vaccine. […] CDC recommends adults ages 60-74 who are at increased risk of severe RSV disease get an RSV vaccine. […] The RSV vaccine is not currently an annual vaccine. […] The RSV vaccine is given as a single dose. […] CDC recommends an RSV vaccine for all adults ages 75 years and older and for adults ages 60-74 years who are at increased risk of severe RSV. […] One dose of RSV vaccine provides protection against RSV disease in adults ages 60 years and older for at least two years. […] Additional data are needed for all three vaccines to determine how long the protection lasts. […] Based on the available data, ACIP and CDC continue to conclude that the benefits of RSV vaccination, in terms of preventable hospitalizations and deaths, outweigh the potential risk for GBS, among adults ages 75 years and older and among adults ages 60-74 years at increased risk of severe RSV disease. […] CDC and FDA will continue to monitor RSV vaccine safety and will share data as they become available.

• #64 RSV Vaccine Guidance for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html

  CDC recommends a single dose of RSV vaccine for older adults to help prevent serious RSV infection and hospitalization. […] Healthcare providers caring for adults aged 6074 years residing in these communities may use clinical judgement, knowledge of local RSV epidemiology, and community incidence of RSV-associated hospitalization to recommend vaccination for a broader population in this age group. […] CDC will continue to monitor real-world RSV vaccine effectiveness during each respiratory virus season. […] CDC does not have a preferential recommendation for any specific vaccine. Eligible older adults should receive whichever vaccine is available. […] Additional surveillance and evaluation activities are ongoing to determine whether adults might benefit from receiving additional RSV vaccine doses in the future. […] The need for additional RSV vaccine doses will be evaluated by ACIP and CDC in the future; recommendations will be updated as needed. […] CDC RSV Surveillance Research.

• #65 RSV Vaccine Guidance for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html

  CDC recommends a single dose of RSV vaccine for older adults to help prevent serious RSV infection and hospitalization. […] Healthcare providers caring for adults aged 6074 years residing in these communities may use clinical judgement, knowledge of local RSV epidemiology, and community incidence of RSV-associated hospitalization to recommend vaccination for a broader population in this age group. […] CDC will continue to monitor real-world RSV vaccine effectiveness during each respiratory virus season. […] CDC does not have a preferential recommendation for any specific vaccine. Eligible older adults should receive whichever vaccine is available. […] Additional surveillance and evaluation activities are ongoing to determine whether adults might benefit from receiving additional RSV vaccine doses in the future. […] The need for additional RSV vaccine doses will be evaluated by ACIP and CDC in the future; recommendations will be updated as needed. […] CDC RSV Surveillance Research.

• #66 RSV (Respiratory Syncytial Virus) | Vermont Department of Health

  https://www.healthvermont.gov/disease-control/immunizations/rsv-respiratory-syncytial-virus

  RSV (Respiratory syncytial virus) is a common respiratory virus that generally spreads during fall and winter. Nearly all children will get RSV for the first time before the age of two. Its possible to get RSV more than once and people can get infected at any age. […] Vaccines are available to protect older adults from severe RSV. Vaccines for pregnant people or an RSV antibody is available to protect babies from severe RSV. […] All adults ages 75 and older should get an RSV vaccine. […] Adults ages 60-74 who are at increased risk of severe RSV should get an RSV vaccine. […] There are three RSV vaccines approved for use in adults 60 and older: GSK’s AREXVY, Moderna’s mRESVIA, and Pfizer’s ABRYSVO. […] RSV is the leading cause of hospitalization in infants in the U.S. […] All babies are recommended to be protected from severe RSV by one of two immunization options.

• #67 Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 | MMWR

  https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm

  To update adult RSV vaccination recommendations, ACIP considered data from previous meetings; new data from randomized, observer-blind, placebo-controlled clinical trials (RCTs) of mResvia; and postlicensure data on Arexvy and Abrysvo. […] ACIP recommended a single dose of any FDA-approved RSV vaccine for all adults aged 75 years and for adults aged 6074 years who are at increased risk for severe RSV disease. […] These recommendations replace the June 2023 shared clinical decision-making recommendation for RSV vaccination for adults aged 60 years and apply to all RSV vaccines licensed for adults aged 60 years (i.e., Arexvy [GSK], Abrysvo [Pfizer], or mResvia [Moderna]). […] The challenges of shared clinical decision-making, along with the updated evidence on balance of benefits and risks, led ACIP in June 2024 to make an age-based recommendation for adults aged 75 years and a risk-based recommendation for those aged 6074 years.

• #68 Limited Awareness and Uptake Gaps of RSV Vaccine in Seniors

  https://www.medscape.com/viewarticle/limited-awareness-and-sociodemographic-disparities-regarding-2025a1000b0f

  Only one tenth of hospitalized adults aged 60 years or older received the respiratory syncytial virus (RSV) vaccine during its first season. Sociodemographic differences were observed, with higher vaccine uptake among those aged 75 years or older, those with pulmonary disease, and those with an immunocompromised status. […] Of the patients included in the overall analysis, only 10.4% were vaccinated. RSV vaccination was associated with being 75 years or older, having pulmonary disease, having an immunocompromised status, having a low or moderate SVI, completing 4 years of college, and completing at least some college or technical training (P .001 for all). […] Efforts to address sociodemographic differences in RSV vaccination may be most effective if they include a holistic approach that addresses general barriers to access to preventive care and overall factors associated with vaccine hesitancy, the authors wrote.

• #69 Respiratory syncytial virus: Time for surveillance across all ages, with a focus on adults — JOGH

  https://jogh.org/2024/jogh-14-03008/

  Therefore, improved RSV surveillance systems are needed to better understand the epidemiology of RSV and inform public health measures. […] The group agreed that a standardised case definition is essential to establish RSV surveillance. […] The group agreed that RSV surveillance should be integrated within broader respiratory pathogen surveillance and diagnostic systems (e.g. COVID-19 or influenza surveillance). […] The group agreed that children below two years of age and adults 60 years of age and above as well as individuals with underlying health conditions should be included in RSV surveillance efforts. […] In conclusion, the expansion of RSV surveillance is important to better understand the epidemiology of RSV in adults as well as to optimise the use of emerging RSV vaccines in this population.

• #70 Limited Awareness and Uptake Gaps of RSV Vaccine in Seniors

  https://www.medscape.com/viewarticle/limited-awareness-and-sociodemographic-disparities-regarding-2025a1000b0f

  Only one tenth of hospitalized adults aged 60 years or older received the respiratory syncytial virus (RSV) vaccine during its first season. Sociodemographic differences were observed, with higher vaccine uptake among those aged 75 years or older, those with pulmonary disease, and those with an immunocompromised status. […] Of the patients included in the overall analysis, only 10.4% were vaccinated. RSV vaccination was associated with being 75 years or older, having pulmonary disease, having an immunocompromised status, having a low or moderate SVI, completing 4 years of college, and completing at least some college or technical training (P .001 for all). […] Efforts to address sociodemographic differences in RSV vaccination may be most effective if they include a holistic approach that addresses general barriers to access to preventive care and overall factors associated with vaccine hesitancy, the authors wrote.

• #71 Respiratory syncytial virus (RSV) FAQs | NCIRS

  https://ncirs.org.au/ncirs-fact-sheets-faqs-and-other-resources/respiratory-syncytial-virus-rsv-frequently-asked

  Currently, two RSV vaccines Arexvy and Abrysvo have been approved by the TGA in Australia for older adults for protection against severe RSV disease. […] In Australia, RSV vaccine is recommended for: all people aged 75 years and over, people aged 60 years and over with conditions that increase their risk of severe RSV, First Nations adults aged 60 years and over. […] The need for future booster doses of RSV vaccine has not yet been established. Currently, only a single dose is recommended. […] For more information on the current status of RSV immunisation products in Australia, see Evaluation of and expected access to new RSV vaccines and long-acting monoclonal antibody (mAB) in Australia.

• #72 RSV Vaccine Guidance for Older Adults | RSV | CDC

  https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html

  CDC recommends a single dose of RSV vaccine for older adults to help prevent serious RSV infection and hospitalization. […] Healthcare providers caring for adults aged 6074 years residing in these communities may use clinical judgement, knowledge of local RSV epidemiology, and community incidence of RSV-associated hospitalization to recommend vaccination for a broader population in this age group. […] CDC will continue to monitor real-world RSV vaccine effectiveness during each respiratory virus season. […] CDC does not have a preferential recommendation for any specific vaccine. Eligible older adults should receive whichever vaccine is available. […] Additional surveillance and evaluation activities are ongoing to determine whether adults might benefit from receiving additional RSV vaccine doses in the future. […] The need for additional RSV vaccine doses will be evaluated by ACIP and CDC in the future; recommendations will be updated as needed. […] CDC RSV Surveillance Research.

• #73 Deviations in RSV epidemiological patterns and population structures in the United States following the COVID-19 pandemic | Nature Communications

  https://www.nature.com/articles/s41467-024-47757-9

  The use of these recently approved agents and the many ongoing clinical trials have increased the call for expanded genomic surveillance of RSV populations. […] Current genomic surveillance efforts have identified increased genetic diversity in RSV following the COVID-19 pandemic, particularly in RSV-B, but it is unclear how these mutations might impact the efficacy of future therapeutics. […] Our objective in this study was three-fold: (1) To elucidate shifts in RSV epidemiology during and after implementation of NPIs; (2) To test for associations between viral subtype and clinical outcomes in adult populations; and (3) To assess viral genetic diversity over time and its likely impact on upcoming treatment and vaccine efficacy. […] Taken together, these data confirm alterations in RSV epidemiological patterns following the COVID-19 pandemic but suggest these trends were largely driven by infants as opposed to older adults.

• #74 Deviations in RSV epidemiological patterns and population structures in the United States following the COVID-19 pandemic | Nature Communications

  https://www.nature.com/articles/s41467-024-47757-9

  The use of these recently approved agents and the many ongoing clinical trials have increased the call for expanded genomic surveillance of RSV populations. […] Current genomic surveillance efforts have identified increased genetic diversity in RSV following the COVID-19 pandemic, particularly in RSV-B, but it is unclear how these mutations might impact the efficacy of future therapeutics. […] Our objective in this study was three-fold: (1) To elucidate shifts in RSV epidemiology during and after implementation of NPIs; (2) To test for associations between viral subtype and clinical outcomes in adult populations; and (3) To assess viral genetic diversity over time and its likely impact on upcoming treatment and vaccine efficacy. […] Taken together, these data confirm alterations in RSV epidemiological patterns following the COVID-19 pandemic but suggest these trends were largely driven by infants as opposed to older adults.

• #75 Global molecular diversity of RSV – the “INFORM RSV” study | BMC Infectious Diseases | Full Text

  https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05175-4

  Although RSV is recognized as a global health problem, there is no licensed vaccine currently available anywhere in the world. […] The potential risk of enhanced disease has hampered vaccine development such that, even after more than 50 years of effort, no vaccine is available yet. […] Future clinical use of therapeutics, vaccines and mAbs to prevent RSV raises concerns about the emergence of local resistant strains. […] The International Network For Optimal Resistance Monitoring of RSV (INFORM RSV) study will therefore prospectively describe the molecular epidemiology of RSV by monitoring temporal and geographic distribution of whole viral genome sequences. […] In summary, this global prospective study aims at monitoring the molecular epidemiology of RSV to ensure that already approved therapeutics and those in development will be effective against currently circulating strains worldwide.

• #76 Respiratory syncytial virus: Time for surveillance across all ages, with a focus on adults — JOGH

  https://jogh.org/2024/jogh-14-03008/

  Therefore, improved RSV surveillance systems are needed to better understand the epidemiology of RSV and inform public health measures. […] The group agreed that a standardised case definition is essential to establish RSV surveillance. […] The group agreed that RSV surveillance should be integrated within broader respiratory pathogen surveillance and diagnostic systems (e.g. COVID-19 or influenza surveillance). […] The group agreed that children below two years of age and adults 60 years of age and above as well as individuals with underlying health conditions should be included in RSV surveillance efforts. […] In conclusion, the expansion of RSV surveillance is important to better understand the epidemiology of RSV in adults as well as to optimise the use of emerging RSV vaccines in this population.

• #77 Respiratory syncytial virus: Time for surveillance across all ages, with a focus on adults — JOGH

  https://jogh.org/2024/jogh-14-03008/

  Therefore, improved RSV surveillance systems are needed to better understand the epidemiology of RSV and inform public health measures. […] The group agreed that a standardised case definition is essential to establish RSV surveillance. […] The group agreed that RSV surveillance should be integrated within broader respiratory pathogen surveillance and diagnostic systems (e.g. COVID-19 or influenza surveillance). […] The group agreed that children below two years of age and adults 60 years of age and above as well as individuals with underlying health conditions should be included in RSV surveillance efforts. […] In conclusion, the expansion of RSV surveillance is important to better understand the epidemiology of RSV in adults as well as to optimise the use of emerging RSV vaccines in this population.

• #78 The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions | Archivos de Bronconeumología

  https://www.archbronconeumol.org/en-the-path-towards-effective-respiratory-articulo-S0300289623001874

  This paper reflects the view of four Spanish immunization experts on the rational of these decisions and on the efforts being made across the globe to accommodate the new immunization options by 2023. It addresses the need for an improved RSV surveillance system and detailed data on disease burden to assist policy makers in the implementation of an RSV immunization preventive strategy. […] Strengthening RSV surveillance: Establish RSV as a mandatory reportable disease in the EU and provide guidance for harmonized RSV surveillance. Transition to national integrated sentinel respiratory surveillance, built on robust regional surveillance systems. Integrate predictive insights from RSV surveillance with health policies for optimized system capacity and immunization planning. […] Although RSV is not yet a mandatory reportable disease in the European Union/European Economic Area (EU/EEA) level, in 2022, twelve EU/EEA countries had already made RSV a notifiable disease. We are in favour of adding RSV to the list of mandatory notifiable diseases at the EU level, to allow EU-wide data analysis. Guidance for a harmonized RSV surveillance within the EU would also be welcomed.

• #79 Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System

  https://pmc.ncbi.nlm.nih.gov/articles/PMC11973799/

  Our disproportionality analysis indicated signals for various AEs, particularly preterm birth, indicating that reports of preterm birth in conjunction with RSVpreF vaccination were observed more frequently than statistically expected. […] The AEs reported to VAERS among pregnant individuals vaccinated with RSVpreF largely aligned with the safety profile observed in prelicensure studies; however, this analysis also highlights the previously observed safety signal for preterm birth. […] Active surveillance studies focusing on maternal and perinatal outcomes are needed to further evaluate this signal and guide future clinical recommendations. […] The study uses the Vaccine Adverse Event Reporting System (VAERS) database, a U.S. national pharmacovigilance system, that provides a near real-time surveillance capacity for identifying rare adverse events not previously detected during prelicensure trials.

• #80 Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System | BMJ Open

  https://bmjopen.bmj.com/content/15/4/e087850

  Active surveillance studies focusing on maternal and perinatal outcomes are needed to further evaluate this signal and guide future clinical recommendations. […] The study uses the Vaccine Adverse Event Reporting System (VAERS) database, a U.S. national pharmacovigilance system, that provides a near real-time surveillance capacity for identifying rare adverse events not previously detected during prelicensure trials. […] The uncertainty surrounding the observed safety signal of preterm birth after RSV vaccination persists, as available clinical data do not allow for a determination of whether this association is coincidental or indicative of a potential risk. […] Given the clinical trial findings and the need to weigh the benefits against the risks, vigilant postmarketing surveillance and close monitoring of reported adverse events following immunization (AEFI) have become indispensable. […] This study provides an early post-authorisation safety analysis of the RSVpreF vaccine among pregnant individuals, drawing on voluntarily submitted reports to VAERS. […] Our analysis highlighted a signal of disproportionate reporting for preterm birth that warrants further investigation.

• #81 New RSV vaccines for older adults can result in individual and societal cost savings, benefits

  https://sph.umich.edu/news/2024posts/new-rsv-vaccine-for-older-adults-can-result-in-individual-and-societal-cost-savings-benefits.html

  Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research. […] The study conducted by researchers at the University of Michigan and the U.S. Centers for Disease Control and Prevention and published in the journal Vaccine, evaluated newly approved RSV vaccines: Arexvy, manufactured by GSK, and Abrysvo, manufactured by Pfizer. […] The CDC recommends a single dose for individuals over 75 and a single dose for those over 60 with increased risk of severe disease. […] According to the U.S. Centers for Disease Control and Prevention, RSV results in 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths of adults 67 and older each year. […] The researchers concluded that RSV vaccination might be cost-effective for adults 60 and older, especially those of more advanced age. […] They noted that reduced vaccine costs and sustained efficacy beyond two RSV seasons could make RSV vaccination more cost-effective for a broader population. […] They also said that uncertainties remain, particularly around long-term vaccine efficacy.

• #82 Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study

  https://www.mdpi.com/2076-393X/12/4/383

  The results of the present study show that nirsevimab immunoprophylaxis at birth was highly effective (88.7%) at preventing hospitalisation due to RSV-associated lower respiratory tract disease in children who were born during the RSV epidemic or in the immediate previous months. […] The high cost of nirsevimab makes an economic evaluation advisable to conclude on the optimal use strategy in each country.

• #83 Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025 | MMWR

  https://www.cdc.gov/mmwr/volumes/74/wr/mm7416a1.htm?s_cid=mm7416a1_w

  To evaluate the association between availability of these products and infant and child RSV-associated hospitalization rates, the rates among children aged 5 years were compared for the 202425 and 201820 RSV seasons using data from the RSV-Associated Hospitalization Surveillance Network (RSV-NET) and New Vaccine Surveillance Network (NVSN). […] The findings suggest the importance of protecting infants born during the RSV season through either maternal vaccination during pregnancy or nirsevimab administration in the first week of life, ideally during the birth hospitalization. […] National immunization survey data indicate the estimated proportion of U.S. infants aged 07 months protected by either maternal vaccination or nirsevimab increased during the 202425 RSV season, from 30% in October 2024 to 66% in February 2025, coinciding with the 202425 RSV-associated hospitalization rate reductions in both surveillance networks, with the largest monthly reductions occurring during peak hospitalization periods. […] These results support the recommendations of the Advisory Committee on Immunization Practices to optimize population-level impact by administering RSV prevention products as early as possible in the season (i.e., before peak RSV transmission) on the basis of local epidemiology.

• #84 Perspectives on preventing RSV disease | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/91/9_suppl_1/S1

  The role of the microbiology laboratory in guiding the clinician in selecting appropriate testing for respiratory viruses will also be addressed in the supplement. […] Wastewater surveillance, ie, systematically checking for infectious agents in the sewer system, provided a valuable tool for monitoring SARS-CoV-2 circulation during the COVID-19 pandemic; surveillance has expanded from 20 to 53 jurisdictions across the United States, with increasing capacity to test for more respiratory pathogens. […] Many considerations and potential unanswered questions that are relevant to the new RSV immunizations will be addressed in this supplement, including the duration of effectiveness, the optimal process for shared decision-making between clinician and patient, real-world effectiveness and postmarketing safety surveillance, and vaccine hesitancy and resistance. […] Understanding and addressing public concerns, misinformation, and vaccine hesitancy are critical for successful vaccine implementation.

Zobacz więcej